Advances in Biomarkers (Technical Insights)

 


This research service outlines the key global developments in the field of biomarkers.
USD 4,950

* Required Fields

USD 4,950

PAY BY INVOICE

Be the first to review this product

Table of Contents

Advances in Biomarkers (Technical Insights), Executive SummaryMacroscopic View of BiomarkersGo Biological with a BiomarkerTypes of BiomarkersOmics to Know-Omics NowScope and MethodologyScope and Segmentation of the Research ServiceResearch MethodologyAdvances in Biomarkers (Technical Insights), Biomarkers in Drug DiscoveryThe Biomarker Method in Drug Discovery and DevelopmentBiomarkers May Relieve the Drug Discovery BottleneckSee Path to a BiomarkerNoteworthy InnovationsBiomarker Serves as a Green Signal for a Small Molecule Drug and a Red Alert for AnotherStack of Biomarkers Aid in Understanding Drug ToxicityProteins Find it Difficult to Remain UndetectedA Clear Vision and View for MetabolomicsCase Studies of Targeted Diagnostics for Targeted TherapeuticsDiagnostic as a Companion to TherapeuticWealth of Research on Anti-EGFR TherapyHIV Takes Diversion and Tricks the DrugCompanion Diagnostics Make a FootprintAdvances in Biomarkers (Technical Insights), Biomarkers in Clinical DiagnosticsThe Biomarker Role in Clinical DiagnosticsBetter Diagnostics is Equal to Better TreatmentNoteworthy Innovations in OncologyNoteworthy Innovation in Nononcology AreasAdvances in Biomarkers (Technical Insights), Strategic Evaluation of the Biomarker IndustryApplication Trend AnalysisBiomarkers Research DirectionBiomarkers Promise to Deliver Sooner in OncologyAHP--Prioritization of Biomarker TechnologiesDefinition of CriteriaAHP Process and Computation for Goal Node and Level 0 CriteriaAHP Process and Computation for Goal Node and Level 1 CriteriaFinal Priorities and Analyst InsightsForce Field AnalysisGrowth Drivers and Growth InhibitorsStrategies for ChangeAdvances in Biomarkers (Technical Insights), Strategic Evaluation of Patents and Key ContactsStrategic Evaluation of PatentsWorld Biomarker IP Portfolio--Drug DiscoveryKey Patents in Oncology--Diagnostics--Pertaining to Developments in Chapter 3.1Key Patents in Nononcology Areas--Diagnostics--Pertaining to Developments in Chapter 3.1Key Contacts and AppendixKey ContactsAppendixAdvances in Biomarkers (Technical Insights), Decision Support DatabaseDatabase TablesGovernment Investment in Biotechnology--World (2002 to 2012)Percent Government R&D Investment in Biotechnology--World (2002 to 2012)Global Pharmaceutical R&D Expenditure (2002 to 2012)Global Percentage Pharmaceutical R&D Expenditure (2002 to 2012)




Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.